

Plasmid construction

Yeast expression plasmids contained either the complete (GALL) or crippled (GALS) Gal1/10 promoter, for galactose inducible/glucose repressible transgene expression¹⁻², and cassette containing a centromere sequence and autonomously replicating sequence for stable copy number control³. The following plasmids have been previously described: pGALL-(*LEU2*), pADH-(*TRP1*)-P35⁴; Caspase-3-lacZ⁵; pGALL-(*TRP1*)-MCS, pGALL-(*TRP1*)-MCS-Bcl-2⁶; pGALL-(*LEU2*)-caspase-1⁷; pGALL-(*LEU2*)-caspase-8⁸, pEF-FLAG-Bcl-x_L⁹, pEF-FLAG-crmA^{T291R}¹⁰. Other plasmids were generated as outlined below. All non-viral genes were human and the inserts in all constructs were verified by sequencing. Phosphorylated oligonucleotides 1345 and 1346 were annealed, then ligated into pGALL-(*LEU2*) which had been cut with BamHI and phosphatased, to produce pGALL-(*LEU2*)-FLAG. Human Bax was amplified using primers 905 and 1577, cut with BglIII and XbaI and ligated into pGALL-(*LEU2*)-FLAG cut with BamHI and XbaI. The coding region of Bcl-x_L was initially amplified using primers 626 and 627, cut with BglIII and XbaI and cloned into F-pIRESneo⁹, then excised using XbaI (blunted with Klenow) and EcoRI and ligated into pADH(*TRP1*), then excised using EcoRI/XhoI and ligated into pGALL(*TRP1*)-MCS to produce pGALL-(*TRP1*)-MCS-Bcl-x_L. The Bcl-w coding region was amplified with primers 842 and 843, cut with EcoRI and NotI and cloned into pGALL-(*TRP1*)-MCS to yield pGALL-(*TRP1*)-MCS-Bcl-w. Custom DNAs for human Mcl-1 and A1 were ordered from Genscript (Piscataway, New Jersey, USA). The coding regions were excised with EcoRI and either PstI (Mcl-1) or NotI (A1) and ligated into pGALL-(*TRP1*)-MCS to produce pGALL-(*TRP1*)-MCS-Mcl-1 and pGALL-(*TRP1*)-MCS-A1. The truncated GALS promoter and terminator² were excised using KpnI and BamHI and cloned into pGALL-(*TRP1*) to yield pGALS-(*TRP1*). E1B19K was amplified from a plasmid donated by Paul Ekert using

primers 1003 and 1004, cut with EcoRI and NotI and cloned into pGALL(*TRP1*)-MCS to give pGALL-(*TRP1*)-E1B19K. The insert was then released by cutting with BamHI and SphI and ligated into pGALS-(*TRP1*) to give pGALS-(*TRP1*)-E1B19K. The DPV022 and SPPV14 coding regions were removed from the pGALL(*TRP1*) plasmids¹¹⁻¹² using BamHI and SphI and ligated into pGALS-(*TRP1*) to produce pGALS-(*TRP1*)-DPV022 and pGALS-(*TRP1*)-SPPV14. The CrmA gene was amplified from pEF-Puro-CrmA¹³ with primers 310 and 311, then cut with EcoRI and NotI and cloned into pGALL-(*HIS3*)² to yield pGALL-(*HIS3*)-CrmA. HA-Puma was excised from HA-Puma-pEF¹⁴ (provided by Paul Ekert) with BglII and XbaI and ligated into pGALL-(*URA3*)⁵ which had been cut with BamHI and XbaI to produce pGALL-(*URA3*)-HA-Puma. GFP^{S65T}-nostop-pGALL(*TRP1*)-MCS was made by amplifying GFP^{S65T} from p416 MET25 GFP^{S65T} (a kind gift from Trevor Lithgow) using primers 1321 and 1548, cutting the product with BglII and SacII, then ligating it into pGALL-(*TRP1*)-MCS digested with BamHI and SacII. Genes encoding pro-survival Bcl-2 relatives were subcloned out of pGALL(*TRP1*)-MCS vectors into this plasmid as EcoRI/XhoI (Bcl-x_L, Bcl-w), EcoRI/ PstI (Mcl-1) or EcoRI/NotI (A1) fragments. Oligonucleotides 1591 and 1592 were annealed and ligated into EcoRI/XbaI-digested pMAL-c2X (New England Biolabs, Ipswich, Massachusetts, USA) to introduce His₆ and FLAG tags downstream of MBP. The gene encoding this fusion product was amplified using primers 1599 and 1600 and ligated into pGALL(*URA*)-2μ, which was created by replacing the PvuI/PvuI fragment containing the CEN6/ARSH4 cassette of pGALL(*URA3*) with the corresponding 2μ ori cassette from pRS426¹⁵. FLAG-pEF was made by ligating annealed oligonucleotides 1541 and 1542 into pEF-puro¹³ cut with BamHI and XbaI. BamHI/XbaI inserts of Bcl-2, Mcl-1, Bcl-w and A1 (partial digest products were used where

necessary) were ligated into FLAG-pEF cut with BamHI and XbaI, to express FLAG-tagged proteins in mammalian cells.

The following oligonucleotides were used for cloning:

310: 5'GGAATTCAGATCTATGGATATCTTCAGGGAAATCGC3'

311: 5'GCACTAGTGCGGCCGCTTAATTAGTTGTTGGAGAGCAATATC3'

626 : 5'GCAGATCTATGTCTCAGAGCAACCGGG3'

627: 5'GCTCTAGACTATTTCCGACTGAAGAGTG3'

842: 5'GGAATTCATGGCGACCCAGCCTCGGC3'

843: 5'CCCCGCGGCCGCTCACTTGCTAGCAAAAAAGGC3'

905: 5'GCAGATCTATGGACGGGTCCGGGGAGCAG3'

1003: 5'GGAATTCATGGAGGCTTGGGAGTGTTTG3'

1004: 5'GAATGCGGCCGCTCATTCCCGAGGGTCCAGGC3'

1321: 5'GCGAGATCTATGGGTAAAGGAGAAGAAGACTTTTC3'

1345: 5'GATCATGGACTACAAGGACGACGATGACAAGG3'

1346: 5'GATCCCTTGTCATCGTCGTCCTTGTAGTCCAT3'

1541: 5'GATCACCATGGACTACAAGGACGACGATGACAAGGGATCCGCAAGCTT
GCT3'

1542: 5'CTAGAGCAAGCTTGCGGATCCCTTGTCATCGTCGTCCTTGTAGTCCATGGT3'

1548: 5'GCTGCACCGCGGAATTCGGATCCTTTGTATAGTTCATCCATGCCATG3 '

1577: 5'CTTTATTATTTTATTTTATTGAGAGGGTGG3'

1591: 5'AATTCATGGACTACAAGGACGACGATGACAAGGGATCCCATCATCATCA
TCATCACTAAT3'

1592: 5'CTAGATTAGTGATGATGATGATGATGGGATCCCTTGTCATCGTCGTCCTTG

TAGTCCATG3'

1599: 5'GTCGGATCCATGAAAATCGAAGAAGGTAAAC3'

1600: 5' TTAAGTTGGGTAACGCCAG3'

REFERENCES

1. Johnston M, Davis RW. Sequences that regulate the divergent GAL1-GAL10 promoter in *Saccharomyces cerevisiae*. *Mol Cell Biol* 1984; **4**(8): 1440-8.
2. Hawkins CJ, Wang SL, Hay BA. A cloning method to identify caspases and their regulators in yeast: identification of *Drosophila* IAP1 as an inhibitor of the *Drosophila* caspase DCP-1. *Proc. Natl. Acad. Sci.* 1999; **96**(6): 2885-2890.
3. Sikorski R, Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in *Saccharomyces cerevisiae*. *Genetics* 1989; **122**: 19-27.
4. Hawkins CJ, Yoo SJ, Petersen EP, Wang SL, Vernooy SY, Hay BA. The *Drosophila* caspase DRONC cleaves following glutamate or aspartate and is regulated by DIAP1, HID, and GRIM. *J. Biol. Chem.* 2000; **275**(35): 27084-27093.
5. Hawkins CJ, Silke J, Verhagen AM, Foster R, Ekert PG, Ashley DM. Analysis of candidate antagonists of IAP-mediated caspase inhibition using yeast reconstituted with the mammalian Apaf-1-activated apoptosis mechanism. *Apoptosis* 2001; **6**(5): 331-338.
6. Jabbour AM, Puryer MA, Yu JY, Lithgow T, Riffkin CD, Ashley DM *et al.* Human Bcl-2 cannot directly inhibit the *Caenorhabditis elegans* Apaf-1 homologue CED-4, but can interact with EGL-1. *J Cell Sci* 2006; **119**(Pt 12): 2572-82.
7. Brand IL, Green MM, Civciristov S, Pantaki-Eimany D, George C, Gort TR *et al.* Functional and biochemical characterization of the baculovirus caspase inhibitor MaviP35. *Cell Death Dis* 2011; **2**: e242.
8. Jabbour AM, Ekert PG, Coulson EJ, Knight MJ, Ashley DM, Hawkins CJ. The p35 relative, p49, inhibits mammalian and *Drosophila* caspases including DRONC and protects against apoptosis. *Cell Death Differ.* 2002; **9**(12): 1311-20.
9. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. *Oncogene* 2001; **20**(41): 5789-98.
10. Ekert PG, Silke J, Vaux DL. Inhibition of apoptosis and clonogenic survival of cells expressing CrmA variants: optimal caspase substrates are not necessarily optimal inhibitors. *EMBO J* 1999; **18**(2): 330-8.

11. Banadyga L, Lam SC, Okamoto T, Kvensakul M, Huang DC, Barry M. Deerpox virus encodes an inhibitor of apoptosis that regulates Bak and Bax. *J Virol* 2011; **85**(5): 1922-34.
12. Okamoto T, Campbell S, Mehta N, Thibault J, Colman PM, Barry M *et al.* Sheeppox Virus SPPV14 Encodes a Bcl-2-like Cell Death Inhibitor that Counters a Distinct Set of Mammalian Pro-apoptotic Proteins. *J Virol* 2012.
13. Hawkins CJ, Uren AG, Hacker G, Medcalf RL, Vaux DL. Inhibition of interleukin 1-beta-converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP. *Proc Natl Acad Sci USA* 1996; **93**(24): 13786-13790.
14. Sandow JJ, Jabbour AM, Condina MR, Daunt CP, Stomski FC, Green BD *et al.* Cytokine receptor signaling activates an IKK-dependent phosphorylation of PUMA to prevent cell death. *Cell Death Differ* 2012; **19**(4): 633-41.
15. Christianson TW, Sikorski RS, Dante M, Shero JH, Hieter P. Multifunctional yeast high-copy-number shuttle vectors. *Gene* 1992; **110**(1): 119-22.